Codebreaker Labs

Every locus resolved to the single base. Three Atlases in build across validated T-cell and fibroblast lanes, with the full indication pipeline.

Human variation is single-nucleotide. CODEX measures it that way: each Atlas a finished, licensable asset of measured data and the models trained on it.

Codebreaker Labs hires for roles editing human cells one nucleotide at a time and measuring variant effects in Boulder, Colorado.

This role analyzes pooled-variant Perturb-seq experiments in primary human cells, from raw single-cell data to model-training datasets.

The company seeks a wet-lab team lead to guide CRISPR screening and phenotyping in primary human cells while maintaining bench involvement.

Hands-on bench science: run CRISPR screens, cell engineering and phenotyping across primary human T cells, fibroblasts and iPSC-derived models.

Built by the people who made genome editing industrial: founders, board and scientific advisors behind CODEX.

Codebreaker Labs edits human cells one nucleotide at a time to measure variant effects, providing single-base data for immunology, oncology, and rare disease.

Codebreaker Tx has filed a notice for an exempt securities offering to raise **$7,399,611** in new funding. The filing with the **U.S. Securities and Exchange Commission (SEC)** confirms the company’s intent to proceed under federal exemptions. The move signals a capital-raising effort, though no additional details on investor participation or use of funds are disclosed.

Oct 2026intelligence360News article

Codebreaker Labs secures $4.5 million in seed funding to advance its genomic AI platform. The Boulder, Colorado-based company links computational predictions with experimental biology by assessing genetic variant impacts on human cells. This platform aims to bridge gaps between AI-driven insights and real-world biological testing.

Sep 2026The SaaS NewsNews article

Codebreaker Labs secures seed funding led by Kickstart to expand its causal genomics platform and launch **Atlas**, the company’s first commercial product. The round supports scaling proprietary genomic data infrastructure for AI applications in life sciences. The platform aims to enable precision medicine by linking genetic variations to biological outcomes.

Sep 2026EIN PresswireNews article

Codebreaker Labs secures **$4.5 million in seed funding** to advance its AI-driven tools for variant effect analysis. The capital will also accelerate laboratory expansion and the recruitment of scientific talent. The company focuses on applying AI to cell biology research.

Sep 2026GenomeWebNews article